BioAtla (BCAB) Competitors $0.50 +0.02 (+3.46%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ENTX, MGNX, ALTS, COYA, BHST, VXRT, ZNTL, SGMT, GNLX, and ZURAShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Entera Bio (ENTX), MacroGenics (MGNX), Janone (ALTS), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), Vaxart (VXRT), Zentalis Pharmaceuticals (ZNTL), Sagimet Biosciences (SGMT), Genelux (GNLX), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Entera Bio MacroGenics Janone Coya Therapeutics BioHarvest Sciences Vaxart Zentalis Pharmaceuticals Sagimet Biosciences Genelux Zura Bio Entera Bio (NASDAQ:ENTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Which has preferable earnings & valuation, ENTX or BCAB? Entera Bio has higher earnings, but lower revenue than BioAtla. Entera Bio is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$181K555.59-$8.89M-$0.25-8.86BioAtla$11M2.67-$123.46M-$1.44-0.35 Does the media refer more to ENTX or BCAB? In the previous week, BioAtla had 3 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for BioAtla and 2 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.93 beat BioAtla's score of 0.31 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ENTX or BCAB? Entera Bio has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Do analysts rate ENTX or BCAB? Entera Bio currently has a consensus price target of $10.00, suggesting a potential upside of 351.67%. BioAtla has a consensus price target of $6.00, suggesting a potential upside of 1,092.84%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Entera Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in ENTX or BCAB? Entera Bio received 155 more outperform votes than BioAtla when rated by MarketBeat users. Likewise, 67.67% of users gave Entera Bio an outperform vote while only 65.79% of users gave BioAtla an outperform vote. CompanyUnderperformOutperformEntera BioOutperform Votes18067.67% Underperform Votes8632.33% BioAtlaOutperform Votes2565.79% Underperform Votes1334.21% Do institutionals & insiders hold more shares of ENTX or BCAB? 14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 10.9% of Entera Bio shares are owned by insiders. Comparatively, 11.5% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ENTX or BCAB more profitable? Entera Bio's return on equity of -107.24% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Entera BioN/A -107.24% -92.29% BioAtla N/A -187.30%-96.33% SummaryEntera Bio beats BioAtla on 10 of the 16 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.32M$2.96B$5.50B$7.96BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-0.3030.1122.6318.55Price / Sales2.67493.41397.30103.38Price / CashN/A168.6838.1834.62Price / Book0.343.176.704.25Net Income-$123.46M-$72.35M$3.23B$248.27M7 Day Performance10.23%0.66%1.36%1.28%1 Month Performance42.41%7.89%3.85%3.75%1 Year Performance-85.07%-22.87%15.87%5.31% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.8816 of 5 stars$0.50+3.5%$6.00+1,092.8%-78.4%$29.32M$11M-0.3060Upcoming EarningsNews CoverageENTXEntera Bio2.1603 of 5 stars$2.28-5.0%$10.00+338.6%+10.7%$103.56M$181,000.00-8.7720Gap DownMGNXMacroGenics4.0159 of 5 stars$1.64-4.1%$7.38+349.7%-88.3%$103.47M$148.34M-1.04430Upcoming EarningsPositive NewsALTSJanoneN/A$6.43+1.7%N/AN/A$103.39M$12.53M0.00170News CoverageGap DownCOYACoya Therapeutics2.0166 of 5 stars$6.17-0.2%$17.00+175.5%-27.2%$103.19M$3.55M-9.496Upcoming EarningsAnalyst ForecastNews CoverageBHSTBioHarvest SciencesN/A$6.26-4.4%$13.00+107.7%N/A$102.82M$25.19M-5.01N/AVXRTVaxart1.4752 of 5 stars$0.45+11.6%$3.00+570.8%-38.5%$102.06M$28.70M-1.09120News CoverageHigh Trading VolumeZNTLZentalis Pharmaceuticals1.9473 of 5 stars$1.42-0.7%$8.24+480.6%-87.2%$101.97M$67.43M-0.57160Upcoming EarningsNews CoverageGap UpSGMTSagimet Biosciences2.819 of 5 stars$3.31+5.1%$22.40+576.7%-11.5%$101.53M$2M-2.318Gap UpGNLXGenelux1.9217 of 5 stars$2.90+0.7%$18.25+529.3%-13.5%$100.35M$8,000.00-3.0510Upcoming EarningsNews CoverageZURAZura Bio3.1003 of 5 stars$1.41+2.9%$14.67+940.2%-63.9%$96.41MN/A-2.663Upcoming EarningsShort Interest ↓News Coverage Related Companies and Tools Related Companies ENTX Alternatives MGNX Alternatives ALTS Alternatives COYA Alternatives BHST Alternatives VXRT Alternatives ZNTL Alternatives SGMT Alternatives GNLX Alternatives ZURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAB Stock Free BCAB Stock Alerts